What GAZYVA is?
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated:
• in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
• in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular
lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.
What Obinutuzumab is?
Obinutuzumab is a humanized anti-CD20 monoclonal antibody.It can be used as a first-line treatment for chronic lymphocytic leukemia in combination with chemotherapy or with venetoclax, as a first-line treatment for follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamustine chemotherapy.